+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019

  • ID: 4901389
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 2467 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • BioIntegrator Ltd
  • EpiDrugs Discovery
  • Insys Therapeutics Inc
  • Novartis AG
  • Sapience Therapeutics Inc
  • MORE
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 127, 81, 1, 10, 198, 36 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 15, 3, 52 and 9 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • BioIntegrator Ltd
  • EpiDrugs Discovery
  • Insys Therapeutics Inc
  • Novartis AG
  • Sapience Therapeutics Inc
  • MORE
Introduction
Glioblastoma Multiforme (GBM) - Overview
Glioblastoma Multiforme (GBM) - Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects
Glioblastoma Multiforme (GBM) - Discontinued Products
Glioblastoma Multiforme (GBM) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019

List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 1st Bio Therapeutics Inc
  • 4D Pharma Plc
  • Aadi Bioscience Inc
  • AbbVie Inc
  • ABM Therapeutics Inc
  • Accendatech Au Pty Ltd
  • Actuate Therapeutics Inc
  • Adastra Pharmaceuticals Inc
  • Adlai Nortye Biopharma Co Ltd
  • Aduro BioTech Inc
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • Aettis Inc
  • Agenus Inc
  • AiVita Biomedical Inc
  • Allianz Pharmascience Ltd
  • Alterity Therapeutics Ltd
  • Amal Therapeutics SA
  • Amasa Technologies Inc
  • Ambrx Inc
  • Amgen Inc
  • AmpliPharm Pharmaceuticals LLC
  • Anchiano Therapeutics Ltd
  • Anew Oncology Inc
  • AngioChem Inc
  • Apac Biotech Pvt Ltd
  • apceth Biopharma GmbH
  • Apexigen Inc
  • APIM Therapeutics AS
  • Apogenix AG
  • Apollomics Inc
  • Apotex Inc
  • Aptamer Sciences Inc
  • Argonaut Therapeutics Ltd
  • Arizona Cancer Therapeutics LLC
  • Arog Pharmaceuticals Inc
  • Arrien Pharmaceuticals LLC
  • Arrogene Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Athenex Inc
  • Aurora BioPharma Inc
  • Avalia Immunotherapies Ltd
  • Aveta Biomics Inc
  • Avid Chemotherapeutics LLC
  • Avidin Ltd
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bayer AG
  • BeiGene Ltd
  • Beijing Eastern Biotech Co Ltd
  • Berg LLC
  • BerGenBio ASA
  • Bexion Pharmaceuticals LLC
  • BeyondBio Inc
  • BeyondSpring Inc
  • Bio-Path Holdings Inc
  • Bio-Thera Solutions Ltd
  • Bioasis Technologies Inc
  • BioIntegrator Ltd
  • Biosion Inc
  • Biovista Inc
  • BioXpress Therapeutics SA
  • Black Diamond Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Boryung ViGenCell Inc
  • Boston Biomedical Inc
  • Breakpoint Therapeutics GmbH
  • Bristol-Myers Squibb Co
  • Candel Therapeutics
  • Cantex Pharmaceuticals Inc
  • CARsgen Therapeutics Ltd
  • CDG Therapeutics Inc
  • Cell Medicine Cooperation
  • CellCure
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Cellivery Therapeutics Inc
  • Cellmid Ltd
  • Celsion Corp
  • Celularity Inc
  • CHA Bio & Diostech Co Ltd
  • CNS Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Curtana Pharmaceuticals Inc
  • Cynata Therapeutics Ltd
  • CytoVac AS
  • Daiichi Sankyo Co Ltd
  • Dalriada Therapeutics Inc
  • Deciphera Pharmaceuticals Inc
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Denovo Biopharma LLC
  • DevaCell Inc
  • Diakonos Research Ltd
  • Diffusion Pharmaceuticals Inc
  • Diverse Biotech Inc
  • Divide and Conquer Ltd
  • DNAtrix Inc
  • Dong-A ST Co Ltd
  • DrugCendR Inc
  • DualTpharma BV
  • Ecrins Therapeutics SAS
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Empirica Therapeutics Inc
  • ENB Therapeutics LLC
  • EnduRx Pharmaceuticals Inc
  • EnGeneIC Ltd
  • Enochian Biosciences Inc
  • Enterome Bioscience SA
  • EntreChem SL
  • EpicentRx Inc
  • EpiDrugs Discovery
  • Epigene Therapeutics Inc
  • Epygen Biotech Pvt Ltd
  • ERC Belgium SA
  • Erytech Pharma SA
  • Eutilex Co Ltd
  • Ever Supreme Bio Technology Co Ltd
  • Everfront Biotech Inc
  • Evgen Pharma Plc
  • F. Hoffmann-La Roche Ltd
  • Falcon Therapeutics Inc
  • Faron Pharmaceuticals Oy
  • Felicitex Therapeutics Inc
  • FirstString Research Inc
  • Flag Therapeutics Inc
  • Flavocure Biotech LLC
  • Fujifilm Holdings Corp
  • Fusion Antibodies Plc
  • Galapagos NV
  • GC Pharma
  • Gene Techno Science Co Ltd
  • Geneius Biotechnology Inc
  • Genenta Science srl
  • Genentech Inc
  • Genexine Inc
  • Genisphere LLC
  • Genoscience Pharma
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GlioCure SAS
  • GlioPharma ApS
  • GO Therapeutics Inc
  • GtreeBNT Co Ltd
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • GW Pharmaceuticals Plc
  • Hamlet Pharma AB
  • Hanmi Pharmaceuticals Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • Hope Biosciences LLC
  • HOX Therapeutics Ltd
  • Humanigen Inc
  • Hutchison MediPharma Ltd
  • Hyperstem Therapeutics Inc
  • i2 Pharmaceuticals Inc
  • Ibex Biosciences LLC
  • Immatics Biotechnologies GmbH
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • Immunitor LLC
  • ImmunityBio Inc
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Immunomic Therapeutics Inc
  • IMV Inc
  • Imvax Inc
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Innovate Biopharmacueticals Inc
  • Innovation Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • InSight Biopharmaceuticals Ltd
  • Instituto Biomar SA
  • Insys Therapeutics Inc
  • Intensity Therapeutics Inc
  • Ipsen SA
  • ISA Pharmaceuticals BV
  • Istari Oncology Inc
  • Janpix Inc
  • Jay Pharma Inc
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jubilant Biosys Ltd
  • Juno Therapeutics Inc
  • JW CreaGene Co Ltd
  • Kadmon Corp LLC
  • Kalgene Pharmaceuticals Inc
  • Kancera AB
  • Karus Therapeutics Ltd
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Komipharm International Co Ltd
  • Kringle Pharma Inc
  • Kyorin Pharmaceutical Co Ltd
  • Lacerta Therapeutics Inc
  • Lauren Sciences LLC
  • Legend Biotech USA Inc
  • Lin Bioscience Inc
  • Lipopharma Therapeutics SL
  • Lixte Biotechnology Holdings Inc
  • MacroGenics Inc
  • Marino Biotechnology Co Ltd
  • Medesis Pharma SA
  • Medical Guidance Systems LLC
  • Medicenna Therapeutics Corp
  • Medicon Pharmaceuticals Inc
  • Medisun Precision Medicine Ltd
  • MedPacto Inc
  • MELEMA Pharma GmbH
  • Merck & Co Inc
  • Merck KGaA
  • Meryx Inc
  • Metis Precision Medicine
  • MetVital Inc
  • MGC Pharmaceuticals Ltd
  • Midatech Pharma Plc
  • Millennium Pharmaceuticals Inc
  • MimiVax LLC
  • MiReven Pty Ltd
  • Molecular Templates Inc
  • Moleculin Biotech LLC
  • Multimmune GmbH
  • Mustang Bio Inc
  • Mycenax Biotech Inc
  • Nanjing Bioheng Biotech Co Ltd
  • Nanjing KAEDI Biotech Inc
  • Nanomerics Ltd
  • NanoPharmaceuticals LLC
  • NantKwest Inc
  • NatureWise Biotech & Medicals Corp
  • Nektar Therapeutics
  • Neon Therapeutics Inc
  • Neonc Technologies Inc
  • NewLink Genetics Corp
  • NMS Group SpA
  • Northlake International LLC
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Noxopharm Ltd
  • Noxxon Pharma AG
  • NuvOx Pharma LLC
  • OGD2 Pharma SAS
  • Omniox Inc
  • OncoArendi Therapeutics SA
  • Oncoceutics Inc
  • Oncologie Inc
  • Oncology Venture U.S. Inc
  • Oncolytics Biotech Inc
  • Onconova Therapeutics Inc
  • OncoResponse Inc
  • Oncorus Inc
  • OncoRx Pharmaceuticals Inc
  • OncoSynergy Inc
  • Oncotelic Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Oryx GmbH & Co KG
  • Ossianix Inc
  • Ovensa Inc
  • Parabon NanoLabs
  • Pascal Biosciences Inc
  • Patrys Ltd
  • PENAO Pty Ltd
  • Peptomyc SL
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • Pharmicell Co Ltd
  • Phoenix Biotechnology Inc
  • Phost'IN SAS
  • Photonamic GmbH & Co KG
  • Plex Pharmaceuticals Inc
  • Prelude Therapeutics Inc
  • Prestige BioPharma Pte Ltd
  • Preveceutical Medical Inc
  • Primevax Immuno Oncology Inc
  • PTC Therapeutics Inc
  • Puma Biotechnology Inc
  • QED Therapeutics Inc
  • Quadriga BioSciences Inc
  • Regeneron Pharmaceuticals Inc
  • Reglagene LLC
  • Regulus Therapeutics Inc
  • ReNeuron Group Plc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Ridgeline Therapeutics LLC
  • Rznomics Inc
  • Salarius Pharmaceuticals Inc
  • Sanofi
  • Sapience Therapeutics Inc
  • Scancell Holdings Plc
  • Seagull Labs (I) Pvt Ltd
  • Seneca Therapeutics Inc
  • Shandong Boan Biological Technology Co Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shenzhen BinDeBio Ltd
  • Siam Bioscience Co Ltd
  • Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
  • Siena Biotech SpA
  • SignalChem Lifesciences Corp
  • SignPath Pharma Inc
  • Silenseed Ltd
  • Singh Biotechnology LLC
  • SixFold Bioscience Ltd
  • SL Bigen Inc
  • SL VaxiGen Inc
  • SOM Biotech SL
  • Speer Medical Technologies LLC
  • STAT3 Therapeutics Inc
  • Stcube Inc
  • Stella Therapeutics Inc
  • StemGen SpA
  • Stemline Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Susavion Biosciences Inc
  • Suzhou Stainwei Biotech Inc
  • Synactix Pharmaceuticals Inc
  • Synchronicity Pharma Inc
  • Synermore Biologics Co Ltd
  • SyntheX Inc
  • Tactical Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Targinta AB
  • Telo Therapeutics Inc
  • Telomium SAS
  • Terpenoid Therapeutics Inc
  • The Palo Alto Research Center
  • TheraBiologics Inc
  • Theralase Technologies Inc
  • Therapeia GmbH & Co KG
  • TheraPten Biosciences Inc
  • Tmunity Therapeutics Inc
  • Tocagen Inc
  • TRACON Pharmaceuticals Inc
  • Transcode Therapeutics Inc
  • Transgene SA
  • Transtarget Inc
  • Triumvira Immunologics Inc
  • Turning Point Therapeutics Inc
  • TVAX Biomedical Inc
  • Tyme Technologies Inc
  • Upsher-Smith Laboratories Inc
  • Vanquish Oncology Inc
  • Vascular Biogenics Ltd
  • Vault Pharma Inc
  • Vaximm AG
  • VBI Vaccines Inc
  • VCN Biosciences SL
  • Vigeo Therapeutics Inc
  • ViruCure Therapeutics Ltd
  • Vivacitas Oncology Inc
  • Wayshine Biopharma Inc
  • WPD Pharmaceuticals Sp Z oo
  • X4 Pharmaceuticals Inc
  • Xonovo Inc
  • Yooyoung Pharm Co Ltd
  • Zata Pharmaceuticals Inc
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
Adroll
adroll